Loading clinical trials...
Loading clinical trials...
Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent Nausea and Vomiting Induced by Cisplatin-Based Doublet Chemotherapy: A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial
Conditions
Interventions
Olanzapine+NK-1 RA+5-HT3 RA
Dexamethasone+NK-1 RA+5-HT3 RA
Locations
1
China
Fifth Affilliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Start Date
February 3, 2020
Primary Completion Date
May 1, 2022
Completion Date
July 1, 2022
Last Updated
July 29, 2022
NCT05838638
NCT06331520
NCT02106494
NCT04054193
NCT05841849
NCT01937156
Lead Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions